print this page
 

Mark Tidswell, MD, Interim Chief

 
Medicine Department   Image  
Critical Care Medicine Division
  • Interim Chief, Critical Care Medicine Division
  • Associate Director, Critical Care Medicine Fellowship Program
  • Associate Professor of Medicine and Surgery, Tufts University School of Medicine
  • Director, Critical Care Research Program
Address
759 Chestnut Street
Springfield, MA 01199
413.794.5439
Mark.Tidswell@baystatehealth.org
 
Education
  • Pulmonary and Critical Care Medicine Fellowship
    University of California
    San Francisco, CA
  • Critical Care Medicine Fellowship
    Stanford University
    Palo Alto, CA
  • Internal Medicine Residency
    Miriam Hospital/Brown University
    Providence, RI
  • Oregon Health Sciences University Medical School
    Portland, OR
 
Areas of Interest
  • Clinical research in severe sepsis and acute lung injury
 
Committee Appointments
  • Member, Ventilator Associate Pneumonia Committee
  • Member, Institutional Review Board
  • Vice Chair, Institutional Review Board
 
Publications
  • Randomized Clinical Trial of Activated Protein C for the Treatment of Acute Lung Injury. American Journal of Respiratory & Critical Care Medicine. 2008;178(6): 618-623.
  • Morris A, Orme J, Truwit J, Steingrub J, GrissomC, Lee K, Li G, Thompson B, Brower R, Tidswell M, Bernard G, Sorenson D, Sward K, Zheng H, Schoenfeld D, Warner H. A replicable method for blood glucose control in critically ill patients. Crit Care Med 2008;36(6): 1787 – 1795.
  • Tidswell M, Tillis W, LaRosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM, and the eritoran study group. Phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist, in patients with severe sepsis. Crit Care Med 2010;38 (1): 72-83.
  • Tidswell M, LaRosa SP, Toll-like receptor 4 antagonist eritoran tetrasodium (E5564), investigational agent for severe sepsis. Expert Review of Anti-infective Therapy,2011;9(5): 507-520.
  • The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Randomized, Placebo-controlled Clinical Trial of an Aerosolized β2-Agonist for Treatment of Acute Lung Injury. Am J Respir Crit Care Med, 184 (5): 561–568, 2011
  • The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network.. Enteral Omega-3 Fatty Acid, γ-Linoleic Acid, and Antioxidant Supplementation in Acute Lung Injury. JAMA, 306 (14): 1574-1581, 2011.
  • The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Initial Trophic vx Full Enteral Feeding in Patients with Acute Lung Injury: The EDEN Randomized Trial. JAMA, 307 (8): 795-803, 2012.
 
Back